Severity
Moderate
FDA Drug recall · Reported February 22, 2023
cGMP Deviation: Raw material recalled by repackager, due to discoloration of the epinephrine API.
Hto Nevada, Inc. recalled New & Improved Blue Gel Anesthetic, to reduce pain and swelling during pain sensitive pro… - a moderate-severity action.
New & Improved Blue Gel Anesthetic, to reduce pain and swelling during pain sensitive pro… was recalled by Hto Nevada, Inc. in February 22, 2023. Reason: cGMP Deviation: Raw material recalled by repackager, due to discoloration of the epinephrine API.. Check the official notice for the remedy. Verify recall #D-0270-2023 with the FDA Drug before acting.
The recall
Hto Nevada, Inc. issued this moderate-severity FDA Drug recall-cGMP Deviation: Raw material recalled by repackager, due to discoloration of the epinephrine API..
Sourced from official FDA Drug enforcement records. Verify recall #D-0270-2023 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0270-2023) was formally reported on February 22, 2023, with the manufacturer initiating the action on February 9, 2023. It is classified under Moderate severity (Class II), with a current status of Terminated. Hto Nevada, Inc. is listed as the recalling firm, operating out of Lake Oswego, OR. Federal records list the affected scope as 4709 bottles.
The documented reason for this recall is: cGMP Deviation: Raw material recalled by repackager, due to discoloration of the epinephrine API. Distribution data in the federal record shows the product reached: Nationwide in the USA and Canada.. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 5 from FDA Drug - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,287 drugs & medications recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
4709 bottles
Related Recalls
6
5 from same agency
New & Improved Blue Gel Anesthetic, to reduce pain and swelling during pain sensitive procedures, 1 oz bottle, distributed by Dermal Source, Portland, OR, www.dermalsource.com 1-888-568-3223. NDC Code: 80069-008-01. Drug Facts- For use by licensed professionals only, Active Ingredients -Lidocaine HCL (5%), Tetracaine HCL (1%) and epinephrine (0.1%).
cGMP Deviation: Raw material recalled by repackager, due to discoloration of the epinephrine API.
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Terminated |
| Recall number | D-0270-2023 |
| Date reported | February 22, 2023 |
| Date initiated | February 9, 2023 |
| Recalling firm | Hto Nevada, Inc. |
| Firm location | Lake Oswego, OR |
| Affected scope | 4709 bottles |
| Distribution | Nationwide in the USA and Canada. |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
AbbVie Inc. · 2026-06-03
Llorens Pharmaceuticals International Division, Inc. · 2026-05-27
Safecor Health, LLC · 2026-05-27
IntegraDose Compounding Services LLC · 2026-05-27
Lupin Pharmaceuticals Inc. · 2026-05-27
Compare this recall with PRED MILD, prednisolone acetate ophthalmic suspension, USP,… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported February 22, 2023. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.